<DOC>
	<DOCNO>NCT00760929</DOCNO>
	<brief_summary>This 4 arm study patient advance Stage IIIb/IV non-small cell cancer ( NSCLC ) fail least one standard chemotherapy regimen determine proportion patient progression-free survival 12 week follow combination therapy R1507 Tarceva placebo Tarceva . Patients randomize one four treatment arm receive R1507 ( 9mg/kg iv ) placebo weekly R1507 ( 16mg/kg iv ) placebo every 3 week . Tarceva ( 150mg oral daily ) administer treatment arm . Other disease-related endpoint include overall survival , objective response rate , time response , time progressive disease duration response also evaluate . The anticipated time study treatment 1-2 year , target sample size &lt; 500 individual .</brief_summary>
	<brief_title>A Study Effect R1507 Combination With Tarceva ( Erlotinib ) Progression-Free Survival Patients With Stage IIIb/IV Non-Small Cell Lung Cancer ( NSCLC ) .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>male female patient &gt; =18 year histologically document inoperable , locally advanced metastatic ( stage IIIB IV ) NSCLC ; patient must fail least one two standard chemotherapy regimen ; measurable disease accord RECIST criterion ; Eastern Cooperative Oncology Group ( ECOG ) performance status ; life expectancy &gt; 12 week . patient active central nervous system ( CNS ) lesion ; prior treatment agent act via insulinlike growth factor 1 receptor ( IGF1R ) inhibition epidermal growth factor receptor ( EGFR ) target ; administration high dos systemic corticosteroid ; radiotherapy 4 week prior study start ; surgery significant traumatic injury last 2 week prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>